https://www.selleckchem.com/products/gdc-0994.html
3mg/dL (95% CI,-4.1 to-2.5mg/dL; 0.001). Estimates for the change for allopurinol versus placebo over time were 1.09 (95% CI, 0.77-1.54) for ACR, 0.77 (95% CI, 0.36-1.63)for NGAL, and 2.36 (95% CI, 0.97-5.7 for TGF-β1. The model did not converge for KIM-1, but Wilcoxon signed rank test showed no significant difference in change from baseline between study groups. There was no significant change observed in CKD-EPI eGFR or cystatin C eGFR. Post hoc analysis and short duration of the study. Uric acid-lowering with allopurinol is no
Like
Comment
Share
